NASDAQ:MEIP
MEI Pharma Stock News
$3.06
+0 (+0%)
At Close: May 03, 2024
Impel Pharmaceuticals Inc. (IMPL) Reports Q1 Loss, Tops Revenue Estimates
01:35pm, Monday, 16'th May 2022 Zacks Investment Research
Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of -8.33% and 9.94%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the sto
InMed Pharmaceuticals Inc. (INM) Reports Q3 Loss, Misses Revenue Estimates
12:45pm, Friday, 13'th May 2022 Zacks Investment Research
InMed Pharmaceuticals Inc. (INM) delivered earnings and revenue surprises of -8.70% and 27.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the sto
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates
11:05pm, Tuesday, 10'th May 2022 Zacks Investment Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -164.71% and 96.51%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the s
10 Top Penny Stocks To Buy For Under $1 May 2022 Edition
10:58pm, Thursday, 05'th May 2022 PennyStocks
Top penny stocks under $1 to watch in May.
The post 10 Top Penny Stocks To Buy For Under $1 May 2022 Edition appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
10 Top Penny Stocks To Buy For Under $1 May 2022 Edition
06:58pm, Thursday, 05'th May 2022
Top penny stocks under $1 to watch in May. The post 10 Top Penny Stocks To Buy For Under $1 May 2022 Edition appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Pacira (PCRX) Q1 Earnings Miss Estimates
01:15pm, Wednesday, 04'th May 2022 Zacks Investment Research
Pacira (PCRX) delivered earnings and revenue surprises of -13.51% and 0.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
5 Penny Stocks To Buy According To Big Money Options Bets Right Now
04:58pm, Wednesday, 30'th Mar 2022 PennyStocks
Penny stocks with interesting options activity today.
The post 5 Penny Stocks To Buy According To Big Money Options Bets Right Now appeared first on Penny Stocks to Buy, Picks, News and Information |
5 Penny Stocks To Buy According To Big Money Options Bets Right Now
12:58pm, Wednesday, 30'th Mar 2022
Penny stocks with interesting options activity today. The post 5 Penny Stocks To Buy According To Big Money Options Bets Right Now appeared first on Penny Stocks to Buy, Picks, News and Information |
Expert Ratings For MEI Pharma
08:20pm, Friday, 25'th Mar 2022 Benzinga
Analysts have provided the following ratings for MEI Pharma (NASDAQ:MEIP) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
4
0
3
0
0
Last
Analysts Cut Price Target On MEI Pharma As Stock Falls To 52-Week Low After Zandelisib Update
06:47pm, Friday, 25'th Mar 2022 Benzinga
The FDA crushed MEI Pharma Inc's (NASDAQ: MEIP) hopes of winning accelerated approval for its PI3K inhibitor, zandelisib, on the strength of phase 2 data.
In the meeting, the FDA informed that a ra
Mei Pharma (MEIP) to Delay Filing With FDA for Lymphoma Drug
06:29pm, Friday, 25'th Mar 2022 Zacks Investment Research
Mei Pharma's (MEIP) FDA filing plans for zandelisib for lymphoma indication get derailed after the agency requests more clinical studies. The stock plummets in after-market trading post this news.
Mei Pharma (MEIP) to Delay Filing With FDA for Lymphoma Drug
03:48pm, Friday, 25'th Mar 2022
Mei Pharma's (MEIP) FDA filing plans for zandelisib for lymphoma indication get derailed after the agency requests more clinical studies. The stock plummets in after-market trading post this news.
Analysts Cut Price Target On MEI Pharma As Stock Falls To 52-Week Low After Zandelisib Update
02:51pm, Friday, 25'th Mar 2022
The FDA crushed MEI Pharma Inc's (NASDAQ: MEIP) hopes of winning accelerated approval for its PI3K inhibitor, zandelisib, on the strength of phase 2 data. In the meeting, the FDA informed that a ran
Benzinga's Top Ratings Upgrades, Downgrades For March 25, 2022
02:02pm, Friday, 25'th Mar 2022 Benzinga
Upgrades
For Aris Water Solutions Inc (NYSE:ARIS), Capital One upgraded the previous rating of Equal-Weight to Overweight. The stock has a 52-week-high of $19.16 and a 52-week-low of $10.06. At the en
10 Biggest Price Target Changes For Friday
11:48am, Friday, 25'th Mar 2022 Benzinga
Jefferies cut the price target on MEI Pharma, Inc. (NASDAQ: MEIP) from $4 to $1. MEI Pharma shares fell 44.2% to $1.01 in pre-market trading.
RBC Capital lowered Axalta Coating Systems Ltd. (NASDA
